Autolus Therapeutics is a promising clinical-stage biotech that is a leader in T-cell programming and manufacturing technology. They have seen rapid growth since launching in 2014, and recently executed a successful US IPO in June that raised $160.4M at a $17 share price and landed them on the Nasdaq (AUTL).
{iframe}https://biobuzz.io/t-cell-therapy-company-selects-maryland-for-new-us-commercial-manufacturing-facility/{/iframe}